Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
Latest news
CEBioForum 2024 is an annual international conference for the biotechnology sector and also the largest industry even...
We are expanding our research portfolio - that's what you'll read about in Puls Biznesu. Editor Marcel Zatoński spoke...
Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...
Polpharma Biologics, an international biotech company dedicated to the development and manufacturing of biosimilars,...
Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars, an...
Amsterdam Munich, Zug – Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (...
3rd of August 2022 U.S. Food and Drug Administration (FDA) approves FYB201/CIMERLITM* (ranibizumab-eqrn), the first and only biosimilar interchangeable with Lucentis®** CIMERLI™ is the only biosimilar approved for all five Lucentis® indications Commercially available in 0.3 mg and 0.5 mg dosages U.S. commercial launch by Coherus BioSciences, Inc. expected in early October 2022 Amsterdam, Munich,...
Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) has accepted the first-ever Biol...
Warszawa, 18 lipca 2022 r. Polpharma Biologics, polska firma biotechnologiczna zajmująca się rozwojem i produkcją leków biologicznych ogłosiła, że Europejska Agencja Leków (European Medicines Agency – EMA) przyjęła wniosek (Marketing Authorization Application – MAA) o wydanie pozwolenia na dopuszczenie do obrotu na terenie Unii Europejskiej – leku biopodobnego zawierającego przeciwciało...